Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors — Stella

Recruiting

Back to Advanced Solid Tumors trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

University of Kansas, Fairway, Kansas

National Institutes of Health Clinical Center, Bethesda, Maryland

Key details

Phase

Early testing

Sponsor

National Cancer Institute (NCI)

Enrollment target

~116 participants

Started

October 2020

Primary completion

December 2027

Age range

12 Years – 120 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov